445680 KR · Curiox BiosystemsMW GOBLIN RESEARCH
Curiox: Verify Conversion into Revenue and Cash Rather Than Order Growth
Analysis date
Published
As of 2026-10-30, the investment view is conservative. CRO adoption signals growth potential, but operating losses widened despite revenue growth. To support the current price, equipment deliveries and recurring revenue must translate into improved earnings and cash generation.
Read the reasoning behind the analysis
The full report includes key metrics, detailed analysis, valuation, and sources.
Read up to three full reports daily without signing in.
Read the full reportWhat this report covers
- The CRO Order Is a Starting Point; Expanded Purchases Remain Unconfirmed
- Contract Termination Highlights the Risk of Converting Orders into Cash
- Cash Resources and Potential Dilution Must Be Considered Together